Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer

Journal of Thoracic Oncology

Volumn 10, Issue 1, 2015, Pages 116-125

  Ueki, Nami ^a   Matsuo, Yukinori ^a   Togashi, Yosuke ^a,b   Kubo, Takeshi ^a   Shibuya, Keiko ^c   Iizuka, Yusuke ^a   Mizowaki, Takashi ^a   Togashi, Kaori ^a   Mishima, Michiaki ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Interstitial lung disease; Lung cancer; Radiation pneumonitis; Stereotactic body radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LINEAR ACCELERATOR; LUNG FUNCTION TEST; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOTHERAPY PLANNING SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC DEVICE; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIATION PNEUMONITIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84926408700     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000359     Document Type: Article

References (46)

1. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861-870.
2. Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998;82:1062-1070.
3. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-3296.
4. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
5. Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403) Int J Radiat Oncol Biol Phys 2010;78:S27-S28.
6. Nagata Y, Hiraoka M, Shibata T, et al. Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer: first report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys 2012;84:S46.
7. Baker R, Han G, Sarangkasiri S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys 2013;85:190-195.
8. Matsuo Y, Shibuya K, Nakamura M, et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012;83:e545-e549.
9. Borst GR, Ishikawa M, Nijkamp J, et al. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 2009;91:307-313.
10. Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012;82:457-462.
11. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007;2:21.
12. Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 2010;5:32.
13. Onishi H, Marino K, Terahara A, et al. Case series study of 26 Patients who developed fatal radiation pneumonitis (RP) after stereotactic body radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2009;75:S62.
14. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007;101:2534-2540.
15. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8.
16. Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010;65:70-76.
17. Chida M, Kobayashi S, Karube Y, et al. Incidence of acute exacerbation of interstitial pneumonia in operated lung cancer: institutional report and review. Ann Thorac Cardiovasc Surg 2012;18:314-317.
18. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg 2008;34:878-881.
19. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 2014;147:1604-1611, e1603.
20. Chiyo M, Sekine Y, Iwata T, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 2003;126:1141-1146.
21. Fujimoto T, Okazaki T, Matsukura T, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg 2003;76:1674-8.
22. Miyazaki K, Satoh H, Kurishima K, et al. Impact of interstitial lung disease on survival for patients with non-small cell lung cancer. Anticancer Res 2009;29:2671-2674.
23. Voltolini L, Bongiolatti S, Luzzi L, et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg 2013;43:e17-e23.
24. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg 2008;136:1357-1363.
25. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722.
26. Travis WD, King Jr TE, Bateman ED, et al. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
27. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
28. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-983.
29. Takayama K, Nagata Y, Negoro Y, et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys 2005;61:1565-1571.
30. Hiraoka M, Matsuo Y, Takayama K. Stereotactic body radiation therapy for lung cancer: achievements and perspectives. Jpn J Clin Oncol 2010;40:846-854.
31. Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1104-1111.
32. R: A language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing, 2013.
33. Iwata H, Shibamoto Y, Baba F, et al. Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis. Radiother Oncol 2011;101:267-270.
34. Makimoto T, Tsuchiya S, Hayakawa K, Saitoh R, Mori M. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol 1999;29:192-197.
35. Sanuki N, Ono A, Komatsu E, et al. Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res 2012;53:110-116.
36. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer 2013;82:260-265.
37. American Association of Physicists in Medicine. Report 85: tissue inhomogeneity corrections for megavoltage photon beams: report of Task Group 65 of the Radiation Therapy Committee. Madison, WI: Medical Physics Publishing, 2004.
38. Mampuya WA, Matsuo Y, Nakamura A, et al. Differences in dose-volumetric data between the analytical anisotropic algorithm and the x-ray voxel Monte Carlo algorithm in stereotactic body radiation therapy for lung cancer. Med Dosim 2013;38:95-99.
39. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995;108:311-315.
40. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
41. Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152(6 Pt 1):1860-1866.
42. Takahashi H, Kuroki Y, Tanaka H, et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000;162:258-263.
43. Guckenberger M, Kestin LL, Hope AJ, et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol 2012;7:542-551.
44. Kinoshita T, Azuma K, Sasada T, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 2012;4:477-482.
45. Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg 2011;92:1812-1817.
46. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007;132:193-199.